Perrigo OTC Brand Journey Detours Into Management, Operating Problems
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
The firm's report of problems in its European branded product business during its earnings briefing prompted a sharp dip in its share price, closing down more than 10% at $130.40, and left analysts looking for its private label OTC business to continue as its growth driver.